Liquid biopsy firm SeekIn said Monday that it has received a CE mark for its cancer recurrence monitoring test, SeekInCure, and is preparing to launch assay kits in the European Union and other countries that recognize the designation.

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.

According to the WeChat public account of Peking Union Medical College Hospital on November 21, the peripheral blood cell image leukocyte assisted recognition software jointly developed by the Laboratory Department of Peking Union Medical College Hospital and Beijing Xiaofly Technology passed

Cue Health on Wednesday afternoon announced that revenues for the third quarter beat both Wall Street expectations and previous guidance from the firm.

DNAscope, a germline variant-calling pipeline from San Jose-based analytics firm Sentieon, achieved superior SNP and indel accuracy as compared to other standard datasets, according to a recent preprint from the company.

The 86th China International Medical Equipment Fair (CMEF) was suspended in consideration of the health and safety of all participants.

A slower-than-expected recovery in certain procedures, including TAVR and spinal cord stimulation, curbed quarterly profit and revenue.

Avacta, a UK-based developer of cancer immunotherapies and diagnostics, said on Tuesday that it has signed an agreement to acquire Launch Diagnostics for up to ￡37 million ($41.9 million).

Lab testing supply firm Biocare Medical said Tuesday that it has acquired Empire Genomics, a provider of molecular probes for cancer research and diagnostics development, for an undisclosed amount.

The US Food and Drug Administration last week granted Emergency Use Authorization for Premier Medical Laboratory Services' Diversified Medical Healthcare SARS-CoV-2 Assay.

The COVID-19 Antigen Home Test manufactured by Assure Tech has been validated by laboratory and clinical studies to meet FDA standards and has been granted EUA. This means that the product can be marketed in the USA and in countries that recognise FDA EUA approval.

Meridian Bioscience reported on Tuesday that its fiscal fourth quarter revenues declined 14 percent year over year.

The US Food and Drug Administration on Tuesday granted Emergency Use Authorization for a molecular COVID-19/flu test from Lucira Health.

The reason why Daan Gene took the initiative to cut the prices of several test reagents is that the market demand for such test reagents has not yet reached a large scale, and it is doubtful whether it is feasible to exchange price for volume.

Agilent Technologies said after the close of the market on Monday that its fiscal fourth quarter revenues grew 11 percent year over year and beat the consensus Wall Street estimate.